Lexaria Bio Science and partner Altria complete Phase One of the development program
Lexaria BioScience (OTCQX: LXRP- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive Vancouver with news the company has seen their Phase One research and development program of oral forms of nicotine delivery finish with Altria Ventures.
Bunka says everything went as planned and now Altria has exercised its right to activate the "First Warrant Tranche Trigger and now has 90 days to provide that payment to retain its current exclusivity in the US market for DehydraTECH.
Bunka says everything went as planned and now Altria has exercised its right to activate the "First Warrant Tranche Trigger and now has 90 days to provide that payment to retain its current exclusivity in the US market for DehydraTECH.
People In This Video
No users are tagged in this video